Back to search
FLT3-mutated Acute Myeloid Leukemia
Clinical trial pipeline · Data from ClinicalTrials.gov
See which FLT3-mutated Acute Myeloid Leukemia trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which FLT3-mutated Acute Myeloid Leukemia trials you may qualify forThis phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and…
This phase I/II trial studies the side effects and best dose of gilteritinib and to see how well it works in combination with azacitidine and venetoclax in trea…
This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin…
This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy t…
The study population consisted of FLT3-ITD-mutated AML patients who were FLT3-ITD-positive before allogeneic hematopoietic stem cell transplantation. This open-…
This phase I trial tests the safety, side effects, and best dose of SNDX-5613 and gilteritinib for treating patients with acute myeloid leukemia that has come b…
The purpose of this study was to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated AML who were ref…
This study will evaluate the safety, efficacy and pharmacokinetics of midostaurin in combination with standard chemotherapy in pediatrics patients with newly di…